Results 81 to 90 of about 405,974 (257)

Why low-dose aspirin persists in recurrent pregnancy loss without APS: cognitive bias and system design

AJOG Global Reports
Low-dose aspirin (LDA) is widely prescribed for recurrent pregnancy loss (RPL) even when antiphospholipid syndrome (APS) is absent, despite high-level evidence showing no improvement in live-birth rate in such cases.
Kentaro Iga, MD, Takeshi Murakoshi, MD, PhD, Hiroshi Adachi, MD, PhD   +2 more
doaj   +1 more source

Hypoplastic Left Heart Syndrome: Is There a Role for Fetal Therapy? [PDF]

Front Pediatr, 2022
Tulzer A, Huhta JC, Hochpoechler J, Holzer K, Karas T, Kielmayer D, Tulzer G.   +6 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

New challenges of fetal therapy in Japan. [PDF]

J Obstet Gynaecol Res, 2022
Wada S, Ozawa K, Sago H.
europepmc   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Legal Discrepancies and Expectations of Women: Abortion, Fetal Therapy, and NICU Care. [PDF]

Hastings Cent Rep, 2023
Scheinerman N, Callahan KP.
europepmc   +1 more source

Fetal Therapies and Maternal-Fetal Tolerance

, 2016
The ability to diagnose and treat genetic diseases before birth represents one of the foremost breakthroughs of modern medicine. While fetal surgery has advanced in the last several decades, the prospect of applying developments in stem cell biology and gene therapy to the fetal environment remains an open frontier.
Porada, Graca Almeida, MacKenzie, Tippi
openaire   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Care Levels for Fetal Therapy Centers. [PDF]

Obstet Gynecol, 2022
Baschat AA, Blackwell SB, Chatterjee D, Cummings JJ, Emery SP, Hirose S, Hollier LM, Johnson A, Kilpatrick SJ, Luks FI, Menard MK, McCullough LB, Moldenhauer JS, Moon-Grady AJ, Mychaliska GB, Narvey M, Norton ME, Rollins MD, Skarsgard ED, Tsao K, Warner BB, Wilpers A, Ryan G.   +22 more
europepmc   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source